Natural killer (NK) cells act as innate immune cells against hepatitis C virus (HCV) infection. Interferon-α (IFN-α) and ribavirin are the standard treatments for patients with HCV infection. This study is aimed at investigating the dynamic changes in the frequency of different subsets of NK cells following treatment in xx chronic hepatitis C (CHC) patients. CHC patients were treated with peg-IFN or IFN-α, and followed up for 72 weeks. The frequency of different subsets of NK in CHC patients was determined longitudinally by flow cytometry. Treatment with the standard therapy increased the percentages of NKp30+, NKp46+, and CD107a+ NK cells, which were positively correlated with the declining of serum HCV-RNA, but not IFN-γ+ NK cells. NKG2A+ and KIR2DL3+ NK cells were associated with an early virological response in CHC patients. Treatment with IFN-α adjusts the balance of activated receptors and inhibitory receptors and enhances the cytotoxic activity of NK cells. Therefore, measuring NK subsets may be valuable for therapeutic responses in CHC patients.
Get full access to this article
View all access options for this article.
References
1.
AhlenstielG, EdlichB, HogdalLJ, RotmanY, NoureddinM, FeldJJ, HolzLE, TiterenceRH, LiangTJ, RehermannB. 2011. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology, 141(4):1231–1239.
2.
AhlenstielG, TiterenceRH, KohC, EdlichB, FeldJJ, RotmanY, GhanyMG, HoofnagleJH, LiangTJ, HellerT, et al. 2010. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology, 138(1):325–335.e1–2.
3.
AmadeiB, UrbaniS, CazalyA, FisicaroP, ZerbiniA, AhmedP, MissaleG, FerrariC, KhakooSI. 2010. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology, 138(4):1536–1545.
4.
BeziatV, DescoursB, ParizotC, DebreP, VieillardV. 2010. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One, 5(8):e11966
5.
BonorinoP, RamzanM, CamousX, Dufeu-DuchesneT, TheluMA, SturmN, DarizA, GuillermetC, PernolletM, ZarskiJP, et al. 2009. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol, 51(3):458–467.
6.
BrookG, SorianoV, BerginC. 2010. European guideline for the management of Hepatitis B and C virus infections, 2010. Int J STD AIDS, 21(10):669–678.
7.
ChiesaMD, SivoriS, CastriconiR, MarcenaroE, MorettaA. 2005. Pathogen-induced private conversations between natural killer and dendritic cells. Trends Microbiol, 13(3):128–136.
8.
CooperMA, FehnigerTA, TurnerSC, ChenKS, GhaheriBA, GhayurT, CarsonWE, CaligiuriMA. 2001. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood, 97(10):3146–3151.
9.
DessoukiO, KamiyaY, NagahamaH, TanakaM, SuzuS, SasakiY, OkadaS. 2010. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem Biophys Res Commun, 393(2):331–337.
10.
Dominguez-VillarM, Garcia-CozarFJ, ChambersBJ. 2012. The effects of Hepatitis C virus core protein on functional responses in the NK cell line YTS. Scand J Immunol, 75(1):54–60.
11.
DunnC, BrunettoM, ReynoldsG, ChristophidesT, KennedyPT, LamperticoP, DasA, LopesAR, BorrowP, WilliamsK, et al. 2007. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med, 204(3):667–680.
12.
EdlichB, AhlenstielG, AzpirozAZ, StoltzfusJ, NoureddinM, SertiE, FeldJJ, LiangTJ, RotmanY, RehermannB. 2012. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology, 55(1):39–48.
13.
GaoB, JeongWI, TianZ. 2008. Liver: an organ with predominant innate immunity. Hepatology, 47(2):729–736.
14.
HadziyannisSJ, SetteHJr., MorganTR, BalanV, DiagoM, MarcellinP, RamadoriG, BodenheimerHJr., BernsteinD, RizzettoM, et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140(5):346–355.
15.
HarrisonRJ, EttorreA, LittleAM, KhakooSI. 2010. Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol, 161(2):306–314.
16.
HoofnagleJH, SeeffLB. 2006. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med, 355(23):2444–2451.
17.
JonckerNT, FernandezNC, TreinerE, VivierE, RauletDH. 2009. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol, 182(8):4572–4580.
18.
KhakooSI, ThioCL, MartinMP, BrooksCR, GaoX, AstemborskiJ, ChengJ, GoedertJJ, VlahovD, HilgartnerM, et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science, 305(5685):872–874.
19.
KnappS, WarshowU, HegazyD, BrackenburyL, GuhaIN, FowellA, LittleAM, AlexanderGJ, RosenbergWM, CrampME, et al. 2010. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology, 51(4):1168–1175.
20.
LavanchyD. 2009. The global burden of hepatitis C. Liver Int, 29 (Suppl 1):74–81.
21.
LinAW, GonzalezSA, Cunningham-RundlesS, DoranteG, MarshallS, TignorA, HaC, JacobsonIM, TalalAH. 2004. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol, 137(2):408–416.
22.
McHutchisonJG, LawitzEJ, ShiffmanML, MuirAJ, GallerGW, McConeJ, NybergLM, LeeWM, GhalibRH, SchiffER, et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 361(6):580–593.
23.
MiyagiT, GilMP, WangX, LoutenJ, ChuWM, BironCA. 2007. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med, 204(10):2383–2396.
24.
MorishimaC, PaschalDM, WangCC, YoshiharaCS, WoodBL, YeoAE, EmersonSS, ShuhartMC, GretchDR. 2006. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology, 43(3):573–580.
25.
NattermannJ, FeldmannG, AhlenstielG, LanghansB, SauerbruchT, SpenglerU. 2006. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut, 55(6):869–877.
26.
NorrisS, CollinsC, DohertyDG, SmithF, McEnteeG, TraynorO, NolanN, HegartyJ, O'FarrellyC. 1998. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol, 28(1):84–90.
27.
OlivieroB, VarchettaS, PaudiceE, MicheloneG, ZaramellaM, MavilioD, De FilippiF, BrunoS, MondelliMU. 2009. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology, 137(3):1151–1160, 1160.e1–7.
28.
ParG, BerkiT, PalinkasL, BaloghP, SzeredayL, HalaszM, Szekeres-BarthoJ, MisetaA, HegedusG, MozsikG, et al. 2006. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment]. Orv Hetil, 147(13):591–600.
29.
PelletierS, DrouinC, BedardN, KhakooSI, BruneauJ, ShoukryNH. 2010. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol, 53(5):805–816.
30.
PostJ, RatnarajahS, LloydAR. 2009. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci, 66(5):733–756.
31.
RehermannB, NascimbeniM. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 5(3):215–229.
32.
SmythMJ, CretneyE, KellyJM, WestwoodJA, StreetSE, YagitaH, TakedaK, van DommelenSL, Degli-EspostiMA, HayakawaY. 2005. Activation of NK cell cytotoxicity. Mol Immunol, 42(4):501–510.
33.
StegmannKA, BjorkstromNK, VeberH, CiesekS, RieseP, WiegandJ, HademJ, SuneethaPV, JaroszewiczJ, WangC, et al. 2010. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology, 138(5):1885–1897.
34.
TjwaET, van OordGW, HegmansJP, JanssenHL, WoltmanAM. 2011. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol, 54(2):209–218.
35.
TrobonjacaZ, KrogerA, StoberD, LeithauserF, MollerP, HauserH, SchirmbeckR, ReimannJ. 2002. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol, 168(8):3763–3770.
36.
Vidal-CastineiraJR, Lopez-VazquezA, Diaz-PenaR, Alonso-AriasR, Martinez-BorraJ, PerezR, Fernandez-SuarezJ, MelonS, PrietoJ, RodrigoL, et al. 2010. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol, 84(1):475–481.
YamagiwaS, KamimuraH, IchidaT. 2009. Natural killer cell receptors and their ligands in liver diseases. Med Mol Morphol, 42(1):1–8.
39.
YoonJC, ShiinaM, AhlenstielG, RehermannB. 2009. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology, 49(1):12–21.
40.
ZhuH, DongH, EksiogluE, HemmingA, CaoM, CrawfordJM, NelsonDR, LiuC. 2007. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology, 133(5):1649–1659.
